Affibody and Astra Tech enter into license and research agreement
The scope is development of devices for safe blood management
Affibody will develop Affibody® molecules targeting blood components for removal of harmful proteins from patients' blood. Affibody will receive research funding during three years, milestone payments and royalty on worldwide sales of products developed under the collaboration.
Astra Tech manufactures devices for autologous blood transfusion, i.e. re-infusion of the patient's own blood after surgery. By using Affibody® molecules to remove targeted blood components, efficiency and safety will be further enhanced in such products. Accordingly, patient risks related to blood transfusions will be further reduced.
- This agreement is of great strategic importance as it marks the initiation of a collaboration within the field of therapeutic apheresis, one application within our biotherapeutics effort. Astra Tech's devices for purification of blood are an exiting platform on which to apply our affinity ligands, says Torben Jørgensen, CEO of Affibody.
- Affibody's affinity ligands will enhance the efficiency of our bioseparation products, and most importantly, will reduce the risk for patients receiving blood during surgery, says Peter Selley, CEO of Astra Tech.
Other news from the department business & finance
